PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-65.74%
Both yoy net incomes decline, with AGEN at -18.94%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-40.21%
Negative yoy D&A while AGEN is 7.04%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
147.42%
Deferred tax of 147.42% while AGEN is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-33.50%
Negative yoy SBC while AGEN is 187.11%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
2171.95%
Slight usage while AGEN is negative at -290.79%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
577.15%
AP growth well above AGEN's 199.30%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-447.03%
Both reduce yoy usage, with AGEN at -42.17%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-33.50%
Negative yoy while AGEN is 162.72%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-13.29%
Both yoy CFO lines are negative, with AGEN at -8.78%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
19.79%
Lower CapEx growth vs. AGEN's 40.31%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
19.79%
We have mild expansions while AGEN is negative at -2043.30%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-207.32%
We cut debt repayment yoy while AGEN is 100.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
104.75%
Stock issuance far above AGEN's 100.00%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.